3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Ureteral Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urethral Neoplasms
1
Renal Insufficiency
1
Recurrence
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
Cisplatin
24
Carboplatin
19
Paclitaxel
18
pembrolizumab
12
Gemcitabine
12
Radiotherapy
9
Fluorouracil
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
7
cemiplimab
6
Platinum
6
Nivolumab
6
Docetaxel
6
Cetuximab
6
1,2-diaminocyclohexaneplatinum II citrate
6
epothilone B
5
anlotinib
5
Sunitinib
5
Pemetrexed
5
Oxaliplatin
5
Everolimus
5
Drug Therapy
5
Cyclophosphamide
5
Capecitabine
5
Bevacizumab
5
durvalumab
4
Radiotherapy, Intensity-Modulated
4
Radiation
4
Erlotinib Hydrochloride
4
Celecoxib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma
×
vinflunine
×
Clear all
NCT01529411
2019-04-04
MAJA
Spanish Oncology Genito-Urinary Group
Phase 2
Completed
86 enrolled